Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 vaccine immune responses in follicular lymphoma (FL) patients showed lower antibodies but intact T-cell activity compared to healthy individuals. Treatment factors significantly impacted these responses, highlighting the need for personalized vaccination strategies.
Area Of Science
- Immunology
- Oncology
- Vaccinology
Background
- Follicular lymphoma (FL) patients often have altered immune function, potentially affecting vaccine efficacy.
- Understanding immune responses to COVID-19 vaccines in this population is crucial for optimizing protection.
Purpose Of The Study
- To investigate the immunogenicity of COVID-19 vaccines in patients with follicular lymphoma.
- To identify factors influencing antibody and T-cell responses to vaccination in FL patients.
Main Methods
- Analysis of antibody and T-cell responses to SARS-CoV-2 spike protein in 58 FL patients and 149 healthy controls.
- COVID-19 vaccines (BNT162b2 or ChAdOx1) administered relative to B-cell depleting (rituximab) and chemotherapy (bendamustine or cyclophosphamide).
- Assays included Abbott Architect for antibodies and interferon-gamma ELISpot for T cells.
Main Results
- FL patients demonstrated lower antibody levels but preserved T-cell responses compared to controls.
- Low pre-treatment IgA, vaccine administration during treatment, bendamustine, and high FLIPI-2 score were associated with reduced antibody response.
- B-cell depletion differentially impacted antibody and T-cell responses.
Conclusions
- COVID-19 vaccine immunogenicity in FL patients is multifactorial, influenced by disease and treatment characteristics.
- B-cell depletion has distinct effects on antibody versus T-cell immunity.
- Predictive models identified clinical scenarios with high confidence for dichotomous immune responses.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...